- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Evaxion completes phase 2 trial extension for cancer vaccine | 1 | Investing.com | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 07.04. | Evaxion schließt Phase-2-Studienverlängerung für Krebsimpfstoff ab | 6 | Investing.com Deutsch | ||
| 07.04. | Evaxion completes phase 2 cancer vaccine trial extension | 2 | Investing.com | ||
| 07.04. | Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 | 321 | GlobeNewswire (Europe) | Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data including... ► Artikel lesen | |
| 07.04. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.03. | Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress | 373 | GlobeNewswire (Europe) | Using its pioneering AI-platform, AI-Immunology, Evaxion has,
in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently... ► Artikel lesen | |
| 30.03. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | Notice to convene Evaxion's Annual General Meeting | 419 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, announces that its... ► Artikel lesen | |
| 19.03. | Notice to convene Evaxion's Annual General Meeting | 2 | GlobeNewswire (USA) | ||
| 17.03. | Evaxion presents cancer vaccine data at AACR meeting in April | 1 | Investing.com | ||
| 17.03. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | Evaxion to present new data at AACR Annual Meeting | 599 | GlobeNewswire (Europe) | Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion's AI-Immunology platform... ► Artikel lesen | |
| 06.03. | Evaxion outlines expanded cash runway into 2H 2027 and anticipates data milestones for EVX-01 and EVX-04 | 2 | Seeking Alpha | ||
| 05.03. | Evaxion Biotech ADS GAAP EPS of -$0.02 beats by $0.01 | 4 | Seeking Alpha | ||
| 05.03. | Evaxion Earnings Report: Q4 Overview | 7 | Benzinga.com | ||
| 05.03. | Insights into Evaxion Q4 Earnings | 4 | Benzinga.com | ||
| 05.03. | Evaxion announces business update and full year 2025 financial results | 668 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business... ► Artikel lesen | |
| 05.03. | Evaxion A/S - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
| 05.03. | Evaxion plans to file 2025 annual report later today | 359 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will slightly delay... ► Artikel lesen | |
| 04.03. | Evaxion Biotech's Earnings: A Preview | 1 | Benzinga.com |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,85 | +0,48 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| EVOTEC | 5,390 | 0,00 % | Deutsche Telekom: Einstiegs-Chance?, Evotec, HelloFresh, Steyr Motors und TUI - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 35,915 | 0,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| PAION | 0,047 | -26,19 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| AMGEN | 296,75 | -0,29 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 7,120 | +0,28 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 292,50 | -0,31 % | Stryker To Buy Amplitude Vascular Systems | WASHINGTON (dpa-AFX) - Stryker Corporation (SYK), a medical technology company, said on Monday that it has signed a deal to buy Amplitude Vascular Systems, Inc., a privately held developer of... ► Artikel lesen | |
| BIOGEN | 152,56 | +0,54 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| CRISPR THERAPEUTICS | 48,475 | +0,66 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| OCUGEN | 1,562 | +2,63 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| IMMUNOVANT | 26,550 | +5,65 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,850 | +4,17 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| NURIX THERAPEUTICS | 16,300 | +2,45 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,350 | +0,70 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,040 | +5,25 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,48 % bei einem Aktienkurs von 4,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.